{"id":780960,"date":"2023-08-30T10:03:32","date_gmt":"2023-08-30T14:03:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/"},"modified":"2023-08-30T10:03:32","modified_gmt":"2023-08-30T14:03:32","slug":"crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/","title":{"rendered":"CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ZUG, Switzerland and BOSTON, Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at Citi&#8217;s 18<sup>th<\/sup> Annual Biopharma Conference being held from September 6-7, 2023.<\/p>\n<p align=\"justify\">\n        <strong>Fireside Chat<\/strong><br \/>\n        <br \/>Date: Wednesday, September 6, 2023<br \/>Time: 11:20 a.m. ET<\/p>\n<p align=\"justify\">A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SXu_6tbmxt1NS8q7irnKf5ptZs4Dre8WYCt6gKHpjd2Fj5JQ8Oibgc852VKcrSqc9382N7HxkYOZSivZNfH9HD23uOJt3np59Bk5t93QnHY53k-820XyqcGcJPW3fPtN\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/crisprtx.gcs-web.com\/events<\/a>. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation.<\/p>\n<p>\n        <strong>About CRISPR Therapeutics<\/strong>\n      <\/p>\n<p>CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR\/Cas9 platform. CRISPR\/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&amp;D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wVKNtHmmRoN_6bSuQf7Qs6RmgEltGX3qolKKCnDIWYo6jZxNy7AzeXbZu5pofEp_lRaXVB4nsIvnp3rgZl1lhw==\" rel=\"nofollow noopener\" target=\"_blank\">www.crisprtx.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Susan Kim<br \/>+1-617-307-7503<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=noTVUwXYeHdmONedPMq7JH8qeStKdFTKn2JaubSy11PgWQ7aovb6GHP0iLLJBMXOaJd_6lJK7A0LsxZJKmuIYTSn6WE1ItXNlFq-eTRt2QU=\" rel=\"nofollow noopener\" target=\"_blank\">susan.kim@crisprtx.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Rachel Eides<br \/> +1-617-315-4493<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3KGOIDc3uYZ5MrofC--zuRYOoJmPZDi0aII12trgPvlRoR_BdivCwgvCahxUhgFVzwEsR6otFPdAKsQNKEtPQIyqxcZcebbBJXPnsnrCxK5Q6GkdymG3ybiYG83qrW04\" rel=\"nofollow noopener\" target=\"_blank\">rachel.eides@crisprtx.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjcwNjcyYTEtY2Q0MS00NjM5LWFjNDMtNTUwMGI2NDNhZDgxLTEwNjE0ODI=\/tiny\/CRISPR-Therapeutics-AG.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at Citi&#8217;s 18th Annual Biopharma Conference being held from September 6-7, 2023. Fireside Chat Date: Wednesday, September 6, 2023Time: 11:20 a.m. ET A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780960","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CRISPR Therapeutics to Participate in Citi&#039;s 18th Annual Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR Therapeutics to Participate in Citi&#039;s 18th Annual Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at Citi&#8217;s 18th Annual Biopharma Conference being held from September 6-7, 2023. Fireside Chat Date: Wednesday, September 6, 2023Time: 11:20 a.m. ET A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company &hellip; Continue reading &quot;CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T14:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference\",\"datePublished\":\"2023-08-30T14:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/\"},\"wordCount\":274,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/\",\"name\":\"CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=\",\"datePublished\":\"2023-08-30T14:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference - Market Newsdesk","og_description":"ZUG, Switzerland and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at Citi&#8217;s 18th Annual Biopharma Conference being held from September 6-7, 2023. Fireside Chat Date: Wednesday, September 6, 2023Time: 11:20 a.m. ET A live webcast of the fireside chat will be available on the &#8220;Events &amp; Presentations&#8221; page in the Investors section of the Company&#8217;s website at https:\/\/crisprtx.gcs-web.com\/events. A replay of the webcast will be archived on the Company&#8217;s website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company &hellip; Continue reading \"CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T14:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference","datePublished":"2023-08-30T14:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/"},"wordCount":274,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/","name":"CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=","datePublished":"2023-08-30T14:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzExMCM1Nzg5MTEwIzIwNDk5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-participate-in-citis-18th-annual-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CRISPR Therapeutics to Participate in Citi&#8217;s 18th Annual Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780960"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}